nach oben

Erschienen in:

2018 | OriginalPaper | Buchkapitel

5. Silica-Based Polymeric Gels as Platforms for Delivery of Phosphonate Pharmaceutics

verfasst von : Konstantinos E. Papathanasiou, Maria Vassaki, Argyro Spinthaki, Argyri Moschona, Konstantinos D. Demadis

Erschienen in: Polymer Gels

Verlag: Springer Singapore

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

This chapter focuses on polymeric gel drug delivery systems used for initial immobilization and subsequent controlled release of active pharmaceutical ingredients. The primary focus is on phosphonate-based drugs, which are extensively used for a variety of medicinal applications and pathological conditions. Their most recognizable use is for osteoporosis drugs with the common names: medronate, chlodronate, etidronate, alendronate, zoledronate, obadronate, ibandronate, neridronate, etc. Herein, we present a concise literature overview of this research field, presenting research results on immobilization of phosphonates onto silica-based polymeric gels, with the goal to achieve controlled release of these ingredients into biological fluids.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Polysaccharide-Based Polymer Gels and Their Potential Applications

Nächstes Kapitel Polymeric Hydrogel: A Flexible Carrier System for Drug Delivery

Balas F, Manzano M, Horcajada P, Vallet-Regí M (2006) Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc 128:8116–8117CrossRefPubMed

Belton DJ, Patwardhan SV, Perry CC (2005) Spermine, spermidine and their analogues generate tailored silicas. J Mater Chem 15:4629–4638CrossRef

Belton DJ, Patwardhan SV, Annenkov VV, Danilovtseva EN, Perry CC (2008) From biosilicification to tailored materials: optimizing hydrophobic domains and resistance to protonation of polyamines. Proc Natl Acad Sci USA 105:5963–5968CrossRefPubMedPubMedCentral

Binauld S, Stenzel MH (2013) Acid-degradable polymers for drug delivery: a decade of innovation. Chem Commun 49:2082–2102CrossRef

Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228–1236CrossRefPubMed

Chong ASM, Zhao XS (2003) Functionalization of SBA-15 with APTES and characterization of functionalized materials. J Phys Chem B 107:12650–12657CrossRef

Coradin T, Eglin D, Livage J (2004) The silicomolybdic acid spectrophotometric method and its application to silicate/biopolymer interaction studies. Spectroscopy 18:567–576CrossRef

Cremers SC, Pillai G, Papapoulos SE (2005) Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551–570CrossRefPubMed

Demadis KD (2008) Silica scale inhibition relevant to desalination technologies: progress and recent developments. In: Delgado DJ, Moreno P (eds) Desalination research progress. Nova Science Publishers, Inc., New York, pp 249–259

Dunford JE, Thomspson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl disphosphate syntase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharm Exp Ther 296:235–242

Ehrlich H, Demadis KD, Koutsoukos PG, Pokrovsky O (2010) Modern views on desilicification: biosilica and abiotic silica dissolution in natural and artificial environments. Chem Rev 110:4656–4689CrossRefPubMed

Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 96:133–138CrossRefPubMedPubMedCentral

Fleisch H, Reszka A, Rodan G, Rogers G (2002) Bisphosphonates: mechanisms of action. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology. Academic Press, San Diego, pp 1361–1385

Francis MD, Fogelman I (1987) 99 mTc diphosphonate uptake mechanism on bone. In: Fogelman I (ed) Bone scanning in clinical practice. Springer, New York, pp 7–17CrossRef

Francis MD, Graham R, Russell RGG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264–1266CrossRefPubMed

Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358–1367CrossRefPubMed

Fujisaki J, Tokunaga Y, Takahashi T, Hirose T, Shimojo F, Kagayama A, Hata T (1995) Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: synthesis and in vivo characterization of osteotropic carboxyfluorescein. J Drug Target 3:273–282CrossRefPubMed

Fujisaki J, Tokunaga Y, Sawamoto T, Takahashi T, Kimura S, Shimojo F, Hata T (1996a) Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein. J Drug Target 4:117–123CrossRefPubMed

Fujisaki J, Tokunaga Y, Takahashi T, Murata S, Shimojo F, Hata T (1996b) Physicochemical characterization of bisphosphonic carboxyfluorescein for osteotropic drug delivery. J Pharm Pharmacol 48:798–800CrossRefPubMed

Giger EV, Castagner B, Leroux J-C (2013) Biomedical applications of bisphosphonates. J Control Release 167:175–188CrossRefPubMed

Gil L, Han Y, Opas EE, Rodan GA, Ruel R, Seedor JG, Tyler PC, Young RN (1999) Prostaglandin E2–bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg Med Chem 7:901–919CrossRefPubMed

Gittens SA, Bansal G, Zernicke RF, Uludag H (2005) Designing proteins for bone targeting. Adv Drug Deliv Rev 57:1011–1036CrossRefPubMed

Golomb G, Dixon M, Smith MS, Schoen FJ, Levy RJ (1987) Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating. J Pharm Sci 76:271–276CrossRefPubMed

Gommes C, Blacher S, Goderis B, Pirard R, Heinrichs B, Alie C, Pirard JP (2004) In situ SAXS analysis of silica gel formation with an additive. J Phys Chem B 108:8983–8991CrossRef

Hengst V, Oussoren C, Kissel T, Storm G (2007) Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 331:224–227CrossRefPubMed

Hildebrand M (2008) Diatoms, biomineralization processes, and genomics. Chem Rev 108:4855–4874CrossRefPubMed

Hirabayashi H, Takahashi T, Fujisaki J, Masunaga T, Sato S, Hiroi J, Tokunaga Y, Kimura S, Hata T (2001) Bone specific delivery and sustained release of diclofenac, a non- steroidal anti-inflammatory drug, via bisphosphonic prodrug based on osteotropic drug delivery system (ODDS). J Control Release 70:183–191CrossRefPubMed

Hosain F, Spencer RP, Couthon HM, Sturtz GL (1996) Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gembisphosphonate conjugate of methotrexate. J Nucl Med 37:105–107PubMed

Hughes LG, Vick TA, Wang JH (2004) Coated Implants. European Patent 1250164

Kennedy JH (1997) HPLC purification of pergolide using silica gel. Org Process Res Dev 1:68–71CrossRef

Lamb HM, Faulds D (1997) Samarium ¹⁵³Sm lexidronam. Drugs Aging 11:413–418CrossRefPubMed

Lehenkari PP, Kellinsalmi M, Näpänkangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ, Azhayev A, Väänänen HK, Hassinen IE (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255–1262CrossRefPubMed

Levy RJ, Wolfrum J, Schoen FJ, Hawley MA, Lund SA, Langer R (1985) Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate. Science 228:190–192CrossRefPubMed

Levy RJ, Johnson TP, Sintov A, Golomb G (1990) Controlled release implants for cardiovascular disease. J Control Release 11:245–254CrossRef

Levy RJ, Qu X, Underwood T, Trachy J, Schoen FJ (1995) Calcification of valved aortic allografts in rats: effects of age, crosslinking, and inhibitors. J Biomed Mater Res 29:217–226CrossRefPubMed

Liu X, Wiswall AT, Rutledge JE, Akhter MP, Cullen DM, Reinhardt RA, Wang D (2008) Osteotropic β-cyclodextrin for local bone regeneration. Biomaterials 29:1686–1692CrossRefPubMedPubMedCentral

Lopez PJ, Gautier C, Livage J, Coradin T (2005) Mimicking biogenic silica nanostructures formation. Curr Nanosci 1:73–83CrossRef

Luckman SP, Hughes DE, Coxon FP, Graham R, Russell RG, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589CrossRefPubMed

Mann S, Perry CC, Williams RJP, Fyfe CA, Gobbi GC, Kennedy GJ (1983) The characterisation of the nature of silica in biological systems. J Chem Soc Chem Commun 4:168–170CrossRef

Martin del Valle EM, Galan MA, Carbonell RG (2009) Drug delivery technologies: the way forward in the new decade. Ind Eng Chem Res 48:2475–2486CrossRef

Mashkevich BO (ed) (2007) Drug delivery research advances. Nova Science Publishers Inc., New York

Mestiri M, Benoit JP, Hernigou P, Devissaguet JP, Puisieux F (1995) Cisplatin-loaded poly(methyl methacrylate) implants: a sustained drug delivery system. J Control Release 33:107–113CrossRef

Morse DE (1999) Silicon biotechnology: harnessing biological silica production to construct new materials. Trends Biotechnol 17:230–232CrossRef

Mundy GR (1997) Mechanisms of bone metastasis. Cancer 80:1546–1556CrossRefPubMed

Ning RY (2010) Reactive silica in natural waters—a review. Des Wat Treat 21:79–86CrossRef

Patwardhan SV (2011) Biomimetic and bioinspired silica: recent developments and applications. Chem Commun 47:7567–7582CrossRef

Patwardhan SV, Clarson SJ, Perry CC (2005) On the role(s) of additives in bioinspired silicification. Chem Commun 1113–1121

Perry CC, Keeling-Tucker T (1998) Aspects of the bioinorganic chemistry of silicon in conjunction with the biometals calcium, iron and aluminium. J Inorg Biochem 69:181–191CrossRefPubMed

Ramakrishna S, Mayer J, Wintermantel E, Leong KW (2001) Biomedical applications of polymer-composite materials: a review. Compos Sci Technol 61:1189–1224CrossRef

Rodan GA, Reszka AA (2002) Bisphophonate mechanism of action. Curr Mol Med 2:571–577CrossRefPubMed

Russell RGG, Watts N, Ebetino F, Rogers M (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759CrossRefPubMed

Shakespeare WC, Metcalf CA III, Wang Y, Sundaramoorthi R, Keenan T, Weigele M, Bohacek RS, Dalgarno DC, Sawyer TK (2003) Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Curr Opin Drug Discov Devel 6:729–741PubMed

Shane E (2010) Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 362:1825–1827CrossRefPubMed

Siegel RA, Rathbone MJ (2012) Overview of controlled release mechanisms. In: Siepmann J, Siegel RA, Rathbone MJ (eds) Fundamentals and applications of controlled release drug delivery. Springer, New York, pp 19–43CrossRef

Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70:1–20CrossRefPubMed

Steven CR, Busby GA, Mather C, Tariq B, Lucia Briuglia M, Lamprou DA, Urquhart AJ, Grant MH, Patwardhan SV (2014) Bioinspired silica as drug delivery systems and their biocompatibility. J Mater Chem B 2:5028–5042CrossRefPubMed

Szymura-Oleksiak J, Slosarczyk A, Cios A, Mycek B, Paszkiewicz Z, Szklarczyk S, Stankiewicz D (2001) The kinetics of pentoxifyllinerelease in vivo from drug-loaded hydroxyapatite implants. Ceram Int 27:767–772CrossRef

Thomas JM, Johnson BFG, Raja R, Samkar G, Midgley PA (2003) High-performance nanocatalysts for single-step hydrogenations. Acc Chem Res 36:20–30CrossRefPubMed

Thompson WJ, Thompson DD, Anderson PS, Rodan GA (1989) Polymalonic acids as bone affinity agents. European Patent 0341961

Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM (1999) Polymeric systems for controlled drug release. Chem Rev 99:3181–3198CrossRefPubMed

Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999) Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491–494CrossRefPubMed

Walcarius A, Etienne M, Lebeau B (2003) Rate of access to the binding sites in organically modified silicates. 2. Ordered mesoporous silicas grafted with amine or thiol groups. Chem Mater 15:2161–2173CrossRef

Walter KA, Tamargo R, Olivi A, Burger PC, Brem H (1995) Intratumoral chemotherapy. Neurosurgery 37:1129–1145CrossRef

Wang GH, Zhang LM (2007) Manipulating formation and drug-release behavior of new sol-gel silica matrix by hydroxypropyl guar gum. J Phys Chem B 111:10665–10670CrossRefPubMed

Weinstein RS, Robertson PK, Manolagas SC (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53–62CrossRefPubMedPubMedCentral

Zhao Z-G (1992) Adsorption of phenylalanine from aqueous solution onto active carbon and silica gel. Chin J Chem 10:325–330CrossRef

Titel: Silica-Based Polymeric Gels as Platforms for Delivery of Phosphonate Pharmaceutics
verfasst von: Konstantinos E. Papathanasiou
Maria Vassaki
Argyro Spinthaki
Argyri Moschona
Konstantinos D. Demadis
Verlag: Springer Singapore
Buch: Polymer Gels
Print ISBN: 978-981-10-6082-3

Electronic ISBN: 978-981-10-6083-0

Copyright-Jahr: 2018
DOI: https://doi.org/10.1007/978-981-10-6083-0_5

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht